Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects - Abzena

Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects

23 July 2019

San Diego, USA July 2019 – Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to Abzena’s leadership in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Synaffix technology with high scientific quality.

Jonathan Goldman, MD, Abzena CEO added:

“Abzena believes in patient first drug development. Our expertise and experience with Synaffix GlycoConnect™ and HydraSpace™ technology further advances our leadership across multiple platforms in ADC.  We look forward to supporting our customers as they leverage Synaffix technology to rapidly advance ADCs from IND stage into early clinical development.”

For more information please contact:

Abzena
Joseph Reeds
Joseph.reeds@abzena.com
+441223 903367

About Abzena

Abzena provides the most complete set of solutions in integrated discovery to clinical phase biopharmaceutical and antibody drug conjugate manufacturing services in the biopharma industry. The company has a global presence to provide support to clients around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity organizations, headquartered in New York City. For more information, please visit www.abzena.com

 

Interested in our services? Get In Touch